Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Management of uncomplicated acute bronchitis in adults.

BIBLIOGRAPHIC SOURCE(S)

  • Michigan Quality Improvement Consortium. Management of uncomplicated acute bronchitis in adults. Southfield (MI): Michigan Quality Improvement Consortium; 2008 May. 1 p.

GUIDELINE STATUS

This is the current release of the guideline.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

The level of evidence grades (A-D) are provided for the most significant recommendations and are defined at the end of the "Major Recommendations" field.

Assessment

  • Perform thorough history (including tobacco use status [A]) and physical exam
  • Assess the likelihood of uncomplicated acute bronchitis using the following items:
    • Acute respiratory infection (ARI) manifested predominantly by cough, with or without sputum production lasting no more than 3 weeks
    • No clinical evidence of pneumonia
    • Common cold, acute asthma, or exacerbation of chronic obstructive pulmonary disease (COPD) have been ruled out as cause of cough
    • Consider other diagnoses if cough persists greater than 3 weeks

Diagnosis

Clinical Information and Testing

  • Presumed diagnosis of acute bronchitis:
    • Acute respiratory infection (ARI) and cough with or without sputum production lasting no more than 3 weeks
    • No clinical evidence of pneumonia
  • Viral cultures, serologic assays and sputum analyses should not be routinely performed [C]
  • Chest x-ray is not indicated if all of the following are present [B]:
    • Acute cough and sputum production suggestive of acute bronchitis
    • Heart rate <100 beats/min
    • Respiratory rate <24 breaths/min
    • Oral temperature <38° Celsius  (100.4° Fahrenheit)
    • Chest exam lacks findings of focal consolidation, egophony or fremitus

Treatment

  • Condition is a self-limited respiratory disorder. Symptomatic treatment only. Routine treatment with antibiotics is not justified and should not be offered. Avoid antibiotics [A]
  • Beta2 agonist bronchodilators should not be routinely used to alleviate cough. In select patients with wheezing, treatment with beta2 agonist bronchodilators may be useful [C]
  • Antitussive agents can be offered for short-term symptomatic relief of coughing [C]
  • Mucokinetic (mucolytic) agents are not recommended (no consistent favorable effect) [D]

Education and Counseling

Educate Patient/Family Regarding

Definitions:

Levels of Evidence for the Most Significant Recommendations

  1. Randomized controlled trials
  2. Controlled trials, no randomization
  3. Observational studies
  4. Opinion of expert panel

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • Michigan Quality Improvement Consortium. Management of uncomplicated acute bronchitis in adults. Southfield (MI): Michigan Quality Improvement Consortium; 2008 May. 1 p.

ADAPTATION

DATE RELEASED

2008 May

GUIDELINE DEVELOPER(S)

Michigan Quality Improvement Consortium - Professional Association

SOURCE(S) OF FUNDING

Michigan Quality Improvement Consortium

GUIDELINE COMMITTEE

Michigan Quality Improvement Consortium Medical Directors' Committee

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Physician representatives from participating Michigan Quality Improvement Consortium health plans, Michigan State Medical Society, Michigan Osteopathic Association, Michigan Association of Health Plans, Michigan Department of Community Health and Michigan Peer Review Organization

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Standard disclosure is requested from all individuals participating in the Michigan Quality Improvement Consortium (MQIC) guideline development process, including those parties who are solicited for guideline feedback (e.g., health plans, medical specialty societies). Additionally, members of the MQIC Medical Directors' Committee are asked to disclose all commercial relationships as well.

GUIDELINE STATUS

This is the current release of the guideline.

GUIDELINE AVAILABILITY

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI Institute on July 28, 2008. The information was verified by the guideline developer on July 29, 2008.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which may be reproduced with the citation developed by the Michigan Quality Improvement Consortium.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo